Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week

This study has been completed.

Sponsor:

Information provided by (Responsible Party):

AstraZeneca

ClinicalTrials.gov Identifier:

NCT01308372

First received: February 18, 2011

Last updated: November 4, 2011

Last verified: November 2011

History of Changes

Tracking Information

First Received Date ^ICMJE

February 18, 2011

Last Updated Date

November 4, 2011

Start Date ^ICMJE

October 2011

Primary Completion Date

October 2011 (final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

Evaluation of cardiovascular risk in general practice in France estimated by the SCORE scale [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Original Primary Outcome Measures ^ICMJE

Same as current

Change History

Complete list of historical versions of study NCT01308372 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 2008 scale D'Agostino [ Time Frame: 1 week ] [ Designated as safety issue: No ]
Evaluation of cardiovascular risk in general practice in France estimated by the Framingham 1998 scale Wilson [ Time Frame: 1 week ] [ Designated as safety issue: No ]
Evaluation of arteries age evaluation by SCORE [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Original Secondary Outcome Measures ^ICMJE

Same as current

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Cardiovascular Risk in General Practice in France: Cardiovascular Risk Week

Official Title ^ICMJE

Cardiovascular Risk in General Practice in France

Brief Summary

The purpose of this study is to evaluate the proportion of patients which present a high cardiovascular risk estimated by the SCORE scale, in general practice consultations of the 7 French regions (Paris area, North-East, Paris basin, West, South-West, South- East, Mediterranean area)

Detailed Description

MC MD

Study Type ^ICMJE

Observational

Study Design ^ICMJE

Observational Model: Cohort
Time Perspective: Cross-Sectional

Target Follow-Up Duration

Not Provided

Biospecimen

Not Provided

Sampling Method

Probability Sample

Study Population

Primary care

Condition ^ICMJE

Healthy

Intervention ^ICMJE

Not Provided

Study Group/Cohort (s)

For this group of patients, the cardiovascular risk will be evaluated by several tools: the SCORE scale, the Framingham 2008 scale d'Agostino and the 1998 scale Wilson ;

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

9246

Completion Date

October 2011

Primary Completion Date

October 2011 (final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria:

Without any personal history of coronary disease
Non treated with lipid-lowering agents
Lipid test = 1 year old
Presenting at least one cardiovascular risk
Visiting their General Practitioner

Exclusion Criteria:

Gender

Both

Ages

50 Years and older

Accepts Healthy Volunteers

Yes

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

France

Administrative Information

NCT Number ^ICMJE

NCT01308372

Other Study ID Numbers ^ICMJE

NIS-CFR-XXX-2011/1

Has Data Monitoring Committee

Responsible Party

AstraZeneca

Study Sponsor ^ICMJE

AstraZeneca

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:	Eric BRUCKERT, Pr.	Hôpital Pitié-Salpétrière - Service Endocrinologie-Métabolisme
Principal Investigator:	Jean DALLONGEVILLE, Dr.	Institut Pasteur de Lille - Unité d'Epidémiologie et de santé publique Inserm UMR 744
Principal Investigator:	Jean FERRIERES, Pr.	CHU Rangueil - Service de Cardiologie B - Toulouse
Principal Investigator:	Serge KOWNATOR, Dr.	Thionville -Société Française de Cardiologie

Information Provided By

AstraZeneca

Verification Date

November 2011

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top